Candida Vulvovaginitis in Pregnancy.

In the absence of epidemiologic studies over many decades, there are scant data on the prevalence and natural history of vaginal colonization and symptomatic Candida infections in pregnant women. The hormonal mileau of the vagina during pregnancy undoubtedly enhances Candida colonization and serves as a risk factor for symptomatic expression; however, the frequency, clinical manifestation, and response to therapy is largely based on empiric diagnosis of unsubstantiated disease. For reasons of liability, pregnant women have been largely excluded from controlled clinical treatment studies by the pharmaceutical industry; accordingly, treatment guidelines are dictated by opinions rather than data. As in nongravid women, management of symptomatic pregnant women should be based on confirmed diagnosis and not clinical impression.